Drugs in ATC Class S01EC

Up to Top Level ATC Classes

Up to S - Sensory organs

Up to S01 - OPHTHALMOLOGICALS

Up to S01E - ANTIGLAUCOMA PREPARATIONS AND MIOTICS

Drugs in ATC Class: S01EC - Carbonic anhydrase inhibitors

Tradename	Generic Name
ACETAZOLAMIDE	acetazolamide
DIAMOX	acetazolamide
ACETAZOLAMIDE SODIUM	acetazolamide sodium

Market dynamics and patent landscape for ATC Class S01EC (Carbonic anhydrase inhibitors)

Last updated: April 25, 2026

What does ATC S01EC cover and where is the market concentrated?

ATC S01EC is the class of topical ophthalmic carbonic anhydrase inhibitors (CAIs) used to lower intraocular pressure (IOP) in glaucoma and ocular hypertension. Core molecules historically associated with the class are brinzolamide and dorzolamide (both are carbonic anhydrase inhibitors used as eye drops).

Commercial concentration pattern (market structure)

• Originator-to-generic transition: In ophthalmology, early brand formulations tend to transition to multi-source generics once patents and exclusivity expire. For legacy CAIs, the market has largely moved into genericized competition in many geographies.
• Differentiation is formulation-driven: The most material competitive differences now are formulation, dosing frequency, tolerability, and device/packaging, rather than new active substances, because the core CAIs are mature.
• Class expansion is incremental: Most new entrants in late-stage CAI space have targeted new dosing regimens, preservative systems, or combination products that sit adjacent to S01EC (or are coded under combination ATCs rather than S01EC).

Which products define S01EC pricing and volume dynamics?

From a patent and market-lane perspective, S01EC competition is usually led by:

• Brinzolamide ophthalmic
• Dorzolamide ophthalmic

In practice, market dynamics for these molecules follow three drivers:

1. Dosing convenience: Brinzolamide is often positioned with relatively favorable dosing schedules versus some alternatives, though both are commonly dosed multiple times per day depending on formulation.
2. Ocular tolerability: Formulation details (including preservative choice) affect switching behavior.
3. Payor pressure: In many countries, cost pressure drives substitution among equivalents, compressing pricing and increasing the value of differentiated patient support and pharmacoeconomic profiles.

Competitive implication: For investors and R&D strategists, the S01EC “active” molecule space is mature; competitive advantage typically comes from patentable formulation mechanics (viscosity, osmolarity balance, preservative systems, particle engineering, pH/stability), delivery technologies, and label expansions rather than new chemical entities.

How does the patent landscape look for S01EC carbonic anhydrase inhibitors?

S01EC patenting generally falls into three layers:

1) Compound and composition-of-matter (front-end dominance)

These originate with early development of:

• Brinzolamide
• Dorzolamide

Once those compound rights and initial composition patents expire, the remaining lifecycle protection is typically limited to formulation and method-of-use patents.

2) Formulation patents (persistent, but narrower)

Typical formulation patent themes relevant to topical CAIs include:

• Specific concentration ranges
• pH windows that stabilize drug and maintain comfort
• buffer systems
• vehicle composition (e.g., polymeric viscosity agents)
• preservative system improvements (including lower irritation profiles)
• particle size or micronization specifications (where relevant)

These patents can still matter even when the active itself is genericized, because many regulators and payors accept line extensions and reformulations more readily when they show improved tolerability.

3) Methods of use, dosing regimens, and combinations (adjacent to S01EC codes)

Patent protection can extend through:

• Dosing frequency reductions (when supported by data)
• Switch strategies for patients inadequately controlled on monotherapy
• Fixed combinations (often coded under combination ATCs rather than S01EC)
• Label extensions that support clinical differentiation

Key read-across: Even when a new compound is not in play, strong portfolio strategy often targets adjacent protection in combination products and dosing regimens, which influences market entry sequencing.

What is the likely status of ATC S01EC core assets (brinzolamide/dorzolamide)?

Based on the maturity of these molecules and the typical ophthalmic lifecycle pattern, the core chemical entity patents have largely run their course in most markets. That shifts current patent value toward:

• Reformulation and preservative improvements
• Patient adherence dosing strategies
• Device/packaging and delivery improvements
• Combination products and new indications

This is consistent with how ophthalmic therapy classes behave after initial launch: patent value persists through secondary patents that are narrower and country-specific.

Where do exclusivities and regulatory exclusivity influence competition?

Competition in ophthalmics is shaped not only by patents, but by regulatory protection periods and marketing authorisation pathways:

Patent-driven barriers

• Generic launch often requires either:
  • legal clearance or expiry of relevant claims, or
  • successful challenge/settlement.

Regulatory-driven barriers

• Fixed combinations and reformulations may face different review timelines.
• Where data exclusivity applies, reformulation or combination products can still face time-based limitations even if legacy molecules are generic.

Business implication: In S01EC, “freedom to operate” risk is most acute around:

• specific formulation claim sets
• brand-specific viscosity/pH/preservative formulations
• dose and regimen claims, if protected

How do market dynamics influence R&D strategy for new S01EC entrants?

Given the class maturity, R&D strategies that most often justify development cost are those that can generate patent and reimbursement pull-through:

Strategy that typically aligns with patentability

• Preservative system change with a differentiated tolerability outcome
• Viscosity/vehicle reformulation to improve comfort and residence time
• pH and buffering system optimization to improve tolerability and stability
• Adherence-oriented dosing schedules supported by clinical data
• Combination product development that moves the asset into a protected combination frame

Strategy that typically underperforms for S01EC

• Pure replication of old formulations without a credible patent angle
• Low-differentiation “me-too” entries that rely only on bioequivalence without meaningful clinical or device advantages

What does this mean for investors evaluating the S01EC opportunity?

The investable thesis shifts from “new active” to “defendable differentiation.” For S01EC, the defensible components are usually:

• A formulation package with non-obvious stability/tolerability improvements that supports secondary patents
• A clinical package that supports a label change or differentiated dosing regimen
• A regulatory strategy that uses abbreviated pathways without triggering avoidable IP exposure

The market will reward assets that can:

• reduce switching friction (tolerability, dosing simplicity),
• sustain pricing beyond commodity levels (payor acceptance, evidence-backed outcomes),
• and hold competitive headroom through formulation-specific exclusivity.

Key patent landscape takeaways for S01EC carbonic anhydrase inhibitors

1) Portfolio value sits in secondary patents

For mature CAIs, compound patents have typically expired, so portfolio value rests in:

• formulation composition claims,
• specific ranges and buffer/pH systems,
• preservative system selection,
• viscosity/vehicle choices,
• and method-of-use/dosing windows.

2) Country-by-country claim scope is decisive

Formulation and use claims often remain enforceable in some jurisdictions and not others. For market entry planning, enforceability and claim construction become the gating items rather than the class-level chemistry.

3) Combination and formulation strategy determines timing

A new product’s timeline depends on:

• freedom-to-operate around formulation,
• the presence or absence of blocking patents for the specific formulation,
• and whether the product is positioned as a monotherapy (S01EC lane) or a combination product (adjacent lanes).

---

Key Takeaways

• S01EC is mature in terms of active ingredients, with brinzolamide and dorzolamide defining the class’s historical market lanes.
• Market competition is formulation- and regimen-driven once compound IP expires, with tolerability and dosing convenience determining patient switching and payor behavior.
• Patent value persists in secondary layers: formulation composition, buffer/pH, preservative systems, vehicle/viscosity, and dosing/method-of-use claims.
• Investment and R&D strategies should target defendable formulation and clinical differentiation, not new chemistry alone.

---

FAQs

1) What is the most common therapeutic goal of S01EC drugs?

Lower intraocular pressure (IOP) in glaucoma and ocular hypertension via carbonic anhydrase inhibition.

2) Which molecules are most associated with ATC S01EC?

Brinzolamide and dorzolamide are the principal molecules historically used as topical ophthalmic carbonic anhydrase inhibitors.

3) Why do formulation patents matter more in S01EC than compound patents?

Because the core active-ingredient rights are typically expired or near-expired; later-cycle protection usually concentrates in composition-of-formulation and method-of-use claims.

4) What type of differentiation wins in S01EC competition?

Differentiation in tolerability (often driven by preservative and vehicle), dosing convenience, and stability-oriented formulation choices.

5) How should launch timing be assessed for a new S01EC product?

By evaluating freedom-to-operate against specific formulation and dosing claims in each target jurisdiction, then aligning regulatory strategy with that IP profile.

---

References

1. World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC classification. https://www.whocc.no/atc/ (Accessed 2026-04-25).
2. European Medicines Agency. EPARs and product information for ophthalmic agents (carbonic anhydrase inhibitors). https://www.ema.europa.eu/ (Accessed 2026-04-25).